Li Man, Cai Shi-Ying, Boyer James L
The Liver Center, Yale University School of Medicine, New Haven, CT 06510, USA.
The Liver Center, Yale University School of Medicine, New Haven, CT 06510, USA.
Mol Aspects Med. 2017 Aug;56:45-53. doi: 10.1016/j.mam.2017.06.001. Epub 2017 Jul 1.
Bile acids are synthesized in the liver and are the major component in bile. Impaired bile flow leads to cholestasis that is characterized by elevated levels of bile acid in the liver and serum, followed by hepatocyte and biliary injury. Although the causes of cholestasis have been extensively studied, the molecular mechanisms as to how bile acids initiate liver injury remain controversial. In this chapter, we summarize recent advances in the pathogenesis of bile acid induced liver injury. These include bile acid signaling pathways in hepatocytes as well as the response of cholangiocytes and innate immune cells in the liver in both patients with cholestasis and cholestatic animal models. We focus on how bile acids trigger the production of molecular mediators of neutrophil recruitment and the role of the inflammatory response in this pathological process. These advances point to a number of novel targets where drugs might be judged to be effective therapies for cholestatic liver injury.
胆汁酸在肝脏中合成,是胆汁的主要成分。胆汁流动受损会导致胆汁淤积,其特征是肝脏和血清中胆汁酸水平升高,随后出现肝细胞和胆管损伤。尽管胆汁淤积的病因已得到广泛研究,但胆汁酸引发肝损伤的分子机制仍存在争议。在本章中,我们总结了胆汁酸诱导肝损伤发病机制的最新进展。这些进展包括肝细胞中的胆汁酸信号通路,以及胆汁淤积患者和胆汁淤积动物模型中肝脏胆管细胞和固有免疫细胞的反应。我们重点关注胆汁酸如何触发中性粒细胞募集分子介质的产生以及炎症反应在这一病理过程中的作用。这些进展指出了一些新的靶点,药物可能被判定为治疗胆汁淤积性肝损伤的有效疗法。